Abstract
The worldwide incidence of malignant melanoma has been steadily increasing, and it has become a major public health problem in many countries. Melanoma has been considered as a prototypical “immunogenic” tumor on the basis of clinical observations showing that primary lesions can spontaneously regress and that immunosuppressed individuals have an increased incidence of melanoma. Thus, various immunological therapies have been intensively conducted for the treatment of melanoma. Interleukin(IL)-27 is a IL-12-related heterodimeric cytokine composed of p28 and EBV-induced gene 3 subunits that are structurally related to the p35 and p40 subunits of IL-12, respectively. Recent studies reveal that IL-27 exhibits not only potent antitumor immune activities via cytotoxic T lymphocytes or natural killer cells but also an antiangiogenic effect. We recently clarified that IL-27 possesses an antiproliferative activity on melanoma cells. This review summarizes antitumor responses induced by IL-27 and novel anti-melanoma activities of IL-27.
Keywords: malignant melanoma, immunological therapies, Antitumor Activities, Interleukin-27, cytokine
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Antitumor Activities of Interleukin-27 on Melanoma
Volume: 10 Issue: 1
Author(s): Hiroshi Nagai, Shuntaro Oniki, Susumu Fujiwara, Mingli Xu, Izuru Mizoguchi, Takayuki Yoshimoto and Chikako Nishigori
Affiliation:
Keywords: malignant melanoma, immunological therapies, Antitumor Activities, Interleukin-27, cytokine
Abstract: The worldwide incidence of malignant melanoma has been steadily increasing, and it has become a major public health problem in many countries. Melanoma has been considered as a prototypical “immunogenic” tumor on the basis of clinical observations showing that primary lesions can spontaneously regress and that immunosuppressed individuals have an increased incidence of melanoma. Thus, various immunological therapies have been intensively conducted for the treatment of melanoma. Interleukin(IL)-27 is a IL-12-related heterodimeric cytokine composed of p28 and EBV-induced gene 3 subunits that are structurally related to the p35 and p40 subunits of IL-12, respectively. Recent studies reveal that IL-27 exhibits not only potent antitumor immune activities via cytotoxic T lymphocytes or natural killer cells but also an antiangiogenic effect. We recently clarified that IL-27 possesses an antiproliferative activity on melanoma cells. This review summarizes antitumor responses induced by IL-27 and novel anti-melanoma activities of IL-27.
Export Options
About this article
Cite this article as:
Nagai Hiroshi, Oniki Shuntaro, Fujiwara Susumu, Xu Mingli, Mizoguchi Izuru, Yoshimoto Takayuki and Nishigori Chikako, Antitumor Activities of Interleukin-27 on Melanoma, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (1) . https://dx.doi.org/10.2174/187153010790827920
DOI https://dx.doi.org/10.2174/187153010790827920 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
Current Pharmaceutical Design Prediction of Gene Co-Expression by Quantifying Heterogeneous Features
Current Bioinformatics Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints
Current Medicinal Chemistry Sex-Genetic Interaction in the Risk for Cerebrovascular Disease
Current Medicinal Chemistry Determination of Isoflavones in Legumes by QuEChERS-Capillary Electrophoresis-Electrospray Ionization-Mass Spectrometry
Current Analytical Chemistry Epitope Discovery and Their Use in Peptide Based Vaccines
Current Pharmaceutical Design Biologically Active Selenophenes and Benzo[b]selenophenes
Current Organic Synthesis Poly(ADP-ribosylation) and Neoplastic Transformation: Effect of PARP Inhibitors
Current Pharmaceutical Biotechnology Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)
Current Drug Targets Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine The Influence of Lipophilicity on the Classification of Antitumor Acridinones Evaluated by Principal Component Analysis
Current Pharmaceutical Analysis Colloidal Drug Delivery Systems in Vaccine Delivery
Current Drug Targets DNA Repair Proteins as Molecular Targets for Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Large-scale Investigation of Long Noncoding RNA Secondary Structures in Human and Mouse
Current Bioinformatics Chronic Inflammation and Oxidative Stress as a Major Cause of Age- Related Diseases and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Advances in Efficient Health Communication: Promoting Prevention and Detection of STDs
Current HIV Research Cannabis Phenolics and their Bioactivities
Current Medicinal Chemistry The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Development of Heparanase Inhibitors for Anti-Cancer Therapy
Current Medicinal Chemistry Factors Affecting the Metabolite Productions in Endophytes: Biotechnological Approaches for Production of Metabolites
Current Medicinal Chemistry